Publications by authors named "Aminata Lo"

Article Synopsis
  • In Senegal, a study evaluated the effectiveness of mass drug administration (MDA) as a strategy to reduce malaria incidence, comparing it to the standard seasonal malaria chemoprevention (SMC) methods.
  • The trial was conducted in 60 villages, with one group receiving MDA treatment and the other receiving SMC, both delivered door-to-door.
  • Results showed MDA significantly reduced malaria cases by 55% during the peak transmission season, indicating it may be a more effective intervention than standard care without serious side effects reported.
View Article and Find Full Text PDF
Article Synopsis
  • Despite progress in Senegal, three southeastern regions still face a high burden of malaria, particularly among pregnant women, highlighting a gap in recent studies on this issue.
  • In a 2019 study, 877 pregnant women at 11 health clinics were tested for malaria, revealing a prevalence of 48% among those attending scheduled visits, and a staggering 86% among those showing signs of malaria.
  • The study found that the rapid diagnostic tests (RDT) missed many asymptomatic infections, indicating that more effective prevention methods are needed to address the high prevalence of malaria in pregnant women.
View Article and Find Full Text PDF

Background: The overlap in the epidemiology of malaria and helminths has been identified as a potential area to exploit for the development of an integrated control strategy that may help to achieve elimination of malaria and helminths. A randomized, controlled, observer-blind trial was conducted to assess the feasibility and safety of combining mass drug administration (MDA) for schistosomiasis and soil transmitted helminths (STH) with seasonal malaria chemoprevention (SMC) among children living in Senegal.

Methods: Female and male children aged 1-14 years were randomized 1:1:1, to receive Vitamin A and Zinc on Day 0, followed by SMC drugs (sulfadoxine-pyrimethamine and amodiaquine) on Days 1-3 (control group); or praziquantel and Vitamin A on Day 0, followed by SMC drugs on Days 1-3 (treatment group 1); or albendazole and praziquantel on Day 0, followed by SMC drugs on Days 1-3 (treatment group 2).

View Article and Find Full Text PDF
Article Synopsis
  • Asymptomatic malaria poses a significant challenge to malaria control efforts, and genetic factors in hosts may influence who develops symptoms.
  • Researchers analyzed blood samples from 60 symptomatic and 149 nonfebrile individuals in Southern Ghana to explore genetic polymorphisms associated with malaria symptoms.
  • Results indicated that specific gene variations, particularly in MBL2 54, TNF- 308, and G6PD, are linked to a higher likelihood of exhibiting symptomatic malaria, suggesting that genetics play a crucial role in determining the manifestation of the disease.
View Article and Find Full Text PDF

Background: Asymptomatic malaria infections can serve as potential reservoirs for malaria transmission. The density of parasites contained in these infections range from microscopic to submicroscopic densities, making the accurate detection of asymptomatic parasite carriage highly dependent on the sensitivity of the tools used for the diagnosis. This study sought to evaluate the sensitivities of a variety of molecular and serological diagnostic tools at determining the prevalence of asymptomatic Plasmodium falciparum parasite infections in two communities with varying malaria parasite prevalence.

View Article and Find Full Text PDF

Background: Malaria surveillance requires powerful tools and strategies to achieve malaria elimination. Rapid diagnostic tests for malaria (RDTs) are easily deployed on a large scale and are helpful sources of parasite DNA. The application of sensitive molecular techniques to these RDTs is a modern tool for improving malaria case detection and drug resistance surveillance.

View Article and Find Full Text PDF

Background: Asymptomatic carriage of Plasmodium falciparum is widespread in adults and children living in malaria-endemic countries. This study identified the prevalence of malaria parasites and the corresponding levels of naturally acquired anti-parasite antibody levels in afebrile adults living in two communities in the Greater Accra Region of Ghana.

Methods: Two cross-sectional studies conducted in January and February 2016 and repeated in July and August 2016 recruited subjects aged between 6 and 75 years from high parasite prevalence (Obom) and low parasite prevalence (Asutsuare) communities.

View Article and Find Full Text PDF

Unlabelled: Background: Diversity in poses a major threat to malaria control and elimination interventions. This study utilized 12 polymorphic microsatellite (MS) markers and the Msp2 marker to examine diversity, multiplicity of infection (MOI) as well as the population structure of parasites circulating in two sites separated by about 92 km and with varying malaria transmission intensities within the Greater Accra Region of Ghana.

Methods: The diversity and MOI of parasites in 160 non-symptomatic volunteers living in Obom (high malaria transmission intensity) and Asutsuare (low malaria transmission intensity) aged between 8 and 60 years was determined using Msp2 genotyping and microsatellite analysis.

View Article and Find Full Text PDF

Co-infection of malaria and intestinal parasites is widespread in sub-Saharan Africa and causes severe disease especially among the poorest populations. It has been shown that an intestinal parasite (helminth), mixed intestinal helminth or Plasmodium parasite infection in a human induces a wide range of cytokine responses, including anti-inflammatory, pro-inflammatory as well as regulatory cytokines. Although immunological interactions have been suggested to occur during a concurrent infection of helminths and Plasmodium parasites, different conclusions have been drawn on the influence this co-infection has on cytokine production.

View Article and Find Full Text PDF

In Senegal, antimalarial drugs used in treatment and prevention of malaria are one of the main reasons for the current success in controlling malaria. However, the successful control of malaria is highly dependent on continued effectiveness of these drugs which may be compromised by the spread of drug resistance. Therefore, surveillance of drug resistance in the malaria parasites is essential.

View Article and Find Full Text PDF

Background: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each month during the transmission season, is recommended for children living in areas of the Sahel where malaria transmission is highly seasonal. The recommendation for SMC is currently limited to children under five years of age, but, in many areas of seasonal transmission, the burden in older children may justify extending this age limit. This study was done to determine the effectiveness of SMC in Senegalese children up to ten years of age.

View Article and Find Full Text PDF
Article Synopsis
  • Seasonal malaria chemoprevention (SMC) aims to reduce malaria illness and death in children by giving antimalarial drugs during peak transmission seasons, specifically using sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) in areas with high malaria rates.
  • A study conducted in Senegal found that children who did not receive SMC (SMC-) had significantly higher IgG antibody responses to malaria antigens compared to those who did receive SMC (SMC+), suggesting that SMC may hinder the natural development of immunity to malaria.
  • The results indicate that while SMC can help prevent malaria, its long-term use might have limited effects on building acquired immunity against the parasite, although other unme
View Article and Find Full Text PDF

Background: Identification of fungal clinical isolates is essential for therapeutic management. In resource-limited settings, identification mostly relies on biochemical tests whose sensitivity and specificity are known to be insufficient for identification of closely related or newly described species. MALDI-TOF has been shown in favored countries to be a reliable and powerful tool for microorganism identification, including yeasts.

View Article and Find Full Text PDF

Background: Malaria remains a major public health problem in developing countries. Then in these countries prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is being implemented.

View Article and Find Full Text PDF

Rapid diagnosis tests (RDTs) allow for the confirmation of malaria diagnosis. In Senegal, RDTs detecting HRP2 have been adopted in 2008 for malaria diagnosis. However, the sustainability of this strategy requires adequate and regular quality control.

View Article and Find Full Text PDF

Senegal has since 2003 used sulphadoxine-pyrimethamine (SP) for Intermittent Preventive Treatment (IPT) of malaria in risk groups. However, the large-scale IPT strategy may result in increasing drug resistance. Our study investigated the possible impact of SP-IPT given to infants and children on the prevalence of SP-resistant haplotypes in the Plasmodium falciparum genes Pfdhfr and Pfdhps, comparing sites with and without IPTi/c.

View Article and Find Full Text PDF
Article Synopsis
  • Malaria is a major health issue in sub-Saharan Africa, particularly affecting children, and seasonal malaria chemoprevention (SMC) is a new strategy used in Senegal to combat this problem by administering a combination of drugs (sulphadoxine-pyrimethamine and amodiaquine) during high transmission seasons.
  • A study conducted from 2008 to 2010 evaluated the safety, feasibility, and cost-effectiveness of SMC in three health districts of central Senegal by tracking genetic mutations in malaria parasites in children under 10.
  • Results showed no significant mutations related to drug resistance in the SMC group and indicated that the prevalence of these mutations was lower in SMC areas
View Article and Find Full Text PDF

Background: Prompt treatment of malaria attacks with arteminisin-based combination therapy (ACT) is an essential tool for malaria control. A new co-blister tablet of artesunate-mefloquine (AM) with 25 mg/kg mefloquine has been developed for the management of uncomplicated malaria attacks. This non-inferiority randomized trial, was conducted to evaluate the efficacy and safety of the new formulation of AM in comparison to artemether-lumefantrine (AL) for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in Senegal.

View Article and Find Full Text PDF

As a result of widespread antimalarial drug resistance, all African countries with endemic malaria have, in recent years, changed their malaria treatment policy. In Senegal, the health authorities changed from chloroquine (CQ) to a combination of sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) in 2003. Since 2006, the artemisinin combination therapies (ACTs) artemether-lumefantrine (AL) and artesunate plus amodiaquine (AS/AQ) were adopted for uncomplicated malaria treatment.

View Article and Find Full Text PDF

Several studies have shown the efficacy of the intermittent preventive treatment (IPT) using sulfadoxine-pyrimethamine (SP) coupled with the expanded program of immunization (EPI) in infants. However, its adoption as a strategy is conditioned by the long-term efficacy of SP. The impact of IPT-SP coupled with the EPI on the prevalence of markers of resistance to SP was evaluated during this study conducted in Southern Senegal.

View Article and Find Full Text PDF

An open randomized clinical trial study was carried out to compare efficacy and tolerability of artesunate mefloquine 25 mg/kg body weight (Artequin paediatric) versus artemether lumefantrine (Coartem) in the treatment of uncomplicated Plasmodium falciparum malaria in children. In each arm, 160 patients were assigned to receive either AS + MQ or AL with 28 days follow-up. The adequate clinical and parasitological response at Day 28 for per protocol analysis was after polymerase chain reaction correction, 100% for AS + MQ and 96.

View Article and Find Full Text PDF

Background: The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria but no studies of its use for prevention have been done in Africa. We did a cluster randomized trial to determine whether piperaquine in combination with either dihydroartemisin (DHA) or sulfadoxine-pyrimethamine (SP) is as effective, and better tolerated, than SP plus amodiaquine (AQ), when used for intermittent preventive treatment in children delivered by community health workers in a rural area of Senegal.

Methods: Treatments were delivered to children 3-59 months of age in their homes once per month during the transmission season by community health workers.

View Article and Find Full Text PDF